Clinical Trials Logo

Hyperbaric Oxygen Therapy clinical trials

View clinical trials related to Hyperbaric Oxygen Therapy.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05289700 Recruiting - Sickle Cell Disease Clinical Trials

Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD)

HBOT-SCD
Start date: September 15, 2022
Phase: Phase 3
Study type: Interventional

This is a randomised, controlled, double-blind, placebo trial of HBOT (intervention) superiority in the treatment of VOC in SCD, to demonstrate the effectiveness of HBOT for the decrease in pain level in the treatment of SCD-VOC.

NCT ID: NCT05078073 Recruiting - Clinical trials for Acute-graft-versus-host Disease

HBOT in the Treatment and Prevention of aGVHD

Start date: October 10, 2021
Phase: N/A
Study type: Interventional

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic strategy for patients with hematopoietic malignancies. However, the therapeutic benefits and wider application of allo-HSCT are limited by acute graft-versus-host disease (aGVHD), the latter remains a major obstacle against long-term survival for this population. New aGVHD prophylactic and therapeutic strategies that are superior in efficacy, safety, cost-effectiveness, and less technically demanding are still in desperate need. Hyperbaric oxygen therapy (HBOT) has been confirmed as an effective and economical therapeutic modality for hemorrhagic cystitis (HC) whether induced by infection or acute graft-versus-host disease (aGVHD) for transplant recipients. However, little is known about its involvement in aGVHD. In this study, the investigators designed a randomized, controlled, and open clinical trial to confirm the safety and efficacy of HBOT on aGVHD in patient underwent allo-HSCT.

NCT ID: NCT05031949 Recruiting - Clinical trials for Hepatocellular Carcinoma Non-Resectable

Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma

CCGLC-003
Start date: October 30, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to explore the efficacy and safety of hyperbaric oxygen therapy plus Camrelizumab as a second-line treatment in patients with advanced hepatocellular carcinoma who have failed at least 1 previous treatment.

NCT ID: NCT04311437 Recruiting - Clinical trials for Hyperbaric Oxygen Therapy

Effect of Self-acupressure on Middle Ear Barotrauma Associated With Hyperbaric Oxygen Therapy

Start date: March 1, 2020
Phase: N/A
Study type: Interventional

Middle ear barotrauma (MEB) is the most common complication during hyperbaric oxygen therapy (HBOT). Though Valsalva and Toynbee maneuvers have been proposed to prevent MEB, still some patients discontinue HBOT due to severe otalgia, hemorrhage or perforation of tympanic membrane associated with HBOT. Currently, there is no optimal prophylactic management for MEB associated with HBOT. The aim of this protocol is to investigate the efficacy of self-acupressure therapy on MEB associated with HBOT.

NCT ID: NCT03144206 Recruiting - Sarcoma Clinical Trials

Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study

Start date: October 19, 2017
Phase: Phase 4
Study type: Interventional

A parallel-group randomized pilot trial at a single institution (Duke University) on the effect of postoperative hyperbaric oxygen therapy on wound healing in patients with soft tissue sarcoma undergoing surgical resection with neo-adjuvant radiation therapy.. Participants will be allocated to either the treatment group (HBOT) or control (standard of care) by computer-generated randomization, stratified by tumor size (≤10cm and >10cm). An unequal randomization of 2:1 will be utilized to provide experience prescribing HBOT to more patients.